Article
Medicine, Research & Experimental
Roberto Dinami, Luca Pompili, Eleonora Petti, Manuela Porru, Carmen D'Angelo, Serena Di Vito, Angela Rizzo, Virginia Campani, Giuseppe De Rosa, Alejandra Bruna, Violeta Serra, Miguel Mano, Mauro Giacca, Carlo Leonetti, Gennaro Ciliberto, Madalena Tarsounas, Antonella Stoppacciaro, Stefan Schoeftner, Annamaria Biroccio
Summary: miR-182-3p is identified as a post-transcriptional regulator of TRF2 and induces DNA damage and apoptosis by reducing TRF2 levels. Treatment with LNPs containing miR-182-3p can inhibit tumor growth in TNBC models and cross the blood-brain barrier for treating brain metastatic lesions.
EMBO MOLECULAR MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Ancuta Jurj, Oana Zanoaga, Lajos Raduly, Vlad Morhan, Zsofia Papi, Cristina Ciocan, Laura-Ancuta Pop, Ioana Berindan-Neagoe, Cornelia Braicu
Summary: The lack of estrogen or progesterone receptors and absence of HER2 amplification/overexpression limit treatment options for triple-negative breast cancer (TNBC). MicroRNAs (miRNAs), particularly miR-29b-3p, have been of interest for TNBC and correlated with overall survival rates. This study explored the potential therapeutic effects of miR-29b-3p inhibition in TNBC cell lines, observing decreased cell proliferation, activation of apoptosis and autophagy, and altered miRNA expression patterns. Target analysis revealed ECM receptor interaction and TP53 signaling as the main predicted targets, with additional validation showing upregulation of MCL1 and TGFB1.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Cecilia Vittori, Duane Jeansonne, Hassan Yousefi, Celeste Faia, Zhen Lin, Krzysztof Reiss, Francesca Peruzzi
Summary: The study reveals that miR-3189-3p exerts its anti-tumor activity in TNBC cells by targeting translational regulatory proteins, leading to the impairment of c-MYC translation and increased sensitivity to doxorubicin. This suggests that miR-3189-3p may be a valuable therapeutic approach for TNBC, which has limited treatment options.
CANCER CELL INTERNATIONAL
(2022)
Article
Biochemistry & Molecular Biology
Ya Fan, Jia Wang, Wen Jin, Yifei Sun, Yuemei Xu, Yipin Wang, Xiubin Liang, Dongming Su
Summary: The study revealed that HRD1 is significantly underexpressed in triple-negative breast cancer (TNBC) and inhibits cancer progression by inducing proteasomal degradation of Vimentin. CircNR3C2 is also downregulated in TNBC and enhances the tumor-suppressive effects of HRD1 through sponging miR-513a-3p. This circNR3C2/miR-513a-3p/HRD1/Vimentin axis negatively regulates TNBC metastasis and may serve as potential prognostic biomarkers for aggressive breast cancer.
Article
Environmental Sciences
Suping Cui, Yong Zhang, Li Xing, Rui Li, Yingshi Piao, Honggang Liu
Summary: In triple-negative breast cancer (TNBC), circDHDDS and DDX5 levels were increased, while miR-362-3p levels were decreased. CircDHDDS depletion inhibited cell proliferation, migration, invasion, and angiogenesis, while promoting cell apoptosis in TNBC cells. MiR-362-3p exerted a tumor suppressive effect by targeting DDX5 in TNBC cells. DDX5 was shown to regulate TNBC development, and circDHDDS modulated DDX5 expression by binding to miR-362-3p.
ENVIRONMENTAL TOXICOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yifeng Hou, Shuang Cai, Shouyang Yu, Hui Lin
Summary: Metformin induces ferroptosis in breast cancer cells by upregulating miR-324-3p, leading to decreased cancer cell viability. The drug promotes ferroptosis by targeting the miR-324-3p/GPX4 axis, suggesting its potential as an anti-cancer agent.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
(2021)
Article
Oncology
Bo-Hao Zheng, Zhi-Xian He, Juan Zhang, Jing-Jing Ma, Hong-Wei Zhang, Wei Zhu, Zhi-Min Shao, Xiao-Jian Ni
Summary: Low expression of TUSC7 is associated with poor prognosis in TNBC patients. TUSC7 inhibits breast cancer cell growth and metastasis by binding with miR-1224-3P and regulating multiple signaling pathways.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Cell Biology
Liting Jin, Chenggang Luo, Xinhong Wu, Manxiu Li, Shun Wu, Yaojun Feng
Summary: The study revealed that HAGLR promotes the growth of TNBC through the miR-335-3p/WNT2 axis, and this was validated in in vivo tumorigenesis experiments.
Article
Cell Biology
Guoli Shao, Xulong Fan, Pusheng Zhang, Xuewen Liu, Lei Huang, Shufeng Ji
Summary: This study investigates the role of a newly recognized circRNA - circ_0004674 in triple-negative breast cancer (TNBC). The results show that circ_0004674 interacts with miR-377-3p, E2F6, and PNO1, thereby mediating the development and metastasis of TNBC. Silencing of circ_0004674 can suppress the proliferation, cell cycle progression, and migration of TNBC cells, leading to inhibition of tumor growth and metastasis.
CELL BIOLOGY AND TOXICOLOGY
(2023)
Article
Immunology
Yong Li, Wenge Xin, Fang Liu, Fengjuan Li, Chengmin Yang, Changmin Liu, Jiaxin Liu
Summary: This study explores the role of a newly constructed lncRNA-miRNA-mRNA ceRNA network in immune escape in triple-negative breast cancer (TNBC). The ceRNA regulatory network ST7-AS1/miR-301b-3p/BTG1, related to the prognosis of TNBC patients, was identified. In vivo experiments confirmed down-regulated expression of ST7-AS1 and BTG1, and up-regulated expression of miR-301b-3p in orthotopic transplanted tumor tissues of mice. It was found that ST7-AS1 might promote BTG1 expression by competitively binding to miR-301b-3p, thereby restricting immune escape in TNBC.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Peng Li, Yu Zeng, Yudan Chen, Peng Huang, Xinchun Chen, Weidong Zheng
Summary: The overexpression of LRP11-AS1 in TNBC cells showed oncogenic effects possibly by sponging miR-149-3p and regulating the miR-149-3p/NRP2 axis, indicating LRP11-AS1 as a potential diagnostic biomarker and therapeutic target in TNBC.
CANCER CELL INTERNATIONAL
(2022)
Letter
Medicine, General & Internal
Ryan Sun, Lee-Jen Wei
Summary: This article discusses the clinical benefits of pembrolizumab combined with chemotherapy in patients with triple-negative breast cancer. The authors suggest that both hazard values and ratios should be considered when evaluating clinical benefits.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biotechnology & Applied Microbiology
Chuang Du, Jianhua Zhang, Linfeng Zhang, Yingying Zhang, Yan Wang, Jingruo Li
Summary: The study revealed that high expression of hsa_circ_102229 in TNBC leads to poor prognosis. Furthermore, hsa_circ_102229 regulates the expression of PFTK1 by targeting miR-152-3p, promoting migration, proliferation, and invasion of TNBC cells.
JOURNAL OF GENE MEDICINE
(2021)
Article
Oncology
Zhuorong Chen, Xumeng Gong, Chun Cheng, Yinghui Fu, Wanming Wu, Zhihui Luo
Summary: This study found that circ_0001777 positively regulates AKAP12 through sponge miR-95-3p, thereby inhibiting TNBC progression. These findings provide new targets for follow-up research and treatment of TNBC.
CLINICAL BREAST CANCER
(2023)
Article
Medicine, Research & Experimental
Aysegul Gorur, Recep Bayraktar, Cristina Ivan, Hamada Ahmed Mokhlis, Emine Bayraktar, Nermin Kahraman, Didem Karakas, Selda Karamil, Nashwa N. Kabil, Pinar Kanlikilicer, Burcu Aslan, Lulufer Tamer, Zhihui Wang, Vittorio Cristini, Gabriel Lopez-Berestein, George Calin, Bulent Ozpolat
Summary: Deregulation of noncoding RNAs, specifically miR-22-3p, plays a significant role in the pathogenesis of triple-negative breast cancer (TNBC). Restoration of miR-22-3p expression inhibits TNBC cell proliferation, migration, and invasion by targeting eukaryotic elongation factor 2 kinase (eEF2K). Systemic administration of miR-22-3p in lipid nanoparticles effectively suppresses tumor growth in TNBC models, indicating its potential as a novel noncoding RNA-based therapy for TNBC.
MOLECULAR THERAPY-NUCLEIC ACIDS
(2021)